Table 1.

SCFA-induced modulation of PMCA1b and PMCA4b expressions in KATO-III gastric and DLD-1 colon cancer cells: quantitative evaluation

Cell line	Treatment	PMCA1b expression (fold increase)	PMCA4b expression (fold increase)
KATO-III	3 mM Na+-valerate (day 5)	1.7 ± 0.6 (n=10)	5.7 ± 1.9 (n=18)
	3 mM Na+-butyrate (day 4)	2.1 ± 0.5 (n=15)	8.5 ± 1.7 (n=10)
DLD-1	3 mM Na+-valerate (day 5)	2.9 ± 1.0 (n=16)	5.4 ± 0.6 (n=21)
	3 mM Na+-butyrate (day 6)	n.d.*	6.0 ± 1.0 (n=16)

KATO-III and DLD-1 cells were cultured in the absence or in the presence of 3 mM Na⁺-valerate or Na⁺-butyrate for the times indicated in the Table. Cells were TCA-precipitated and Western-blot analysis of the samples followed by the evaluation of the luminograms was performed as described in the “Materials and methods”. The data represent the fold increases of the PMCA1b and PMCA4b expressions at protein level in the differently treated, differentiated cells (means ± S.D. of n ≥10 from at least two independent treatments). The expression levels of the PMCA1b and 4b proteins in untreated cells were used as control values for quantifications.

^*Data are not shown because of the negligible changes in the PMCA1b expression due to 6 days 3 mM Na⁺-butyrate treatment of DLD-1 cells.